Regulated Information

Period

Filter by

Reset

Showing: 1 – 05 of 156 Regulated Information

Show

Sort

Ipsen delivers encouraging sales growth in the first quarter of 2021 despite the pandemic, and confirms its full-year guidance

22 April 2021

Ipsen delivers encouraging sales growth in the first quarter of 2021 despite the pandemic, and confirms its full-year guidance

Attachment

Q1 2021 – Sales presentation (0 bytes)

Webcast replay Q1

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021

11 February 2021

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021

Attachment

FY-2020- Results presentation (0 bytes)

Monthly information relative to the total number of voting rights and shares composing the share capital

12 January 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

This article or press release has no online content. Please download the associated documents for more information.

01 December 2020

Capital Markets Day 2020 – announcement

Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

22 October 2020

Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

Paris (France), 22 October 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2020.

1 … 27 28 29 30 31 32